Cynamon M H, Swenson C E, Palmer G S, Ginsberg R S
Veterans Administration Medical Center, Syracuse, New York.
Antimicrob Agents Chemother. 1989 Aug;33(8):1179-83. doi: 10.1128/AAC.33.8.1179.
Efficacy of liposome-encapsulated amikacin and free amikacin against Mycobacterium avium complex was evaluated in the beige mouse (C57BL/6J-bgJ/bgJ) acute infection model. Approximately 10(7) viable M. avium complex serotype 1 cells for which the MIC of amikacin was 8 micrograms/ml were given intravenously. Treatment was started with encapsulated or free amikacin at approximately 110 or 40 mg/kg of body weight 7 or 14 days later. In the former experiment, treatment was given two or three times per week. In the latter experiment, treatment was given daily for 5 days. The animals were sacrificed 5 days after the last dose. Liver, spleen, and lung were homogenized, and viable cell counts were determined on 7H10 agar. An analysis of variance and subsequent Tukey HSD (honestly significant difference) tests indicated that both encapsulated and free amikacin significantly reduced viable cell counts in each of the organs compared with counts in the control group. Compared with free amikacin, encapsulated amikacin significantly reduced viable cell counts in the liver and spleen. Liposome encapsulation of an active agent appears to be a promising therapeutic approach to M. avium complex infection.
在米色小鼠（C57BL/6J-bgJ/bgJ）急性感染模型中评估了脂质体包裹的丁胺卡那霉素和游离丁胺卡那霉素对鸟分枝杆菌复合群的疗效。静脉注射约10(7)个活菌数的鸟分枝杆菌复合群1型细胞，其丁胺卡那霉素的最低抑菌浓度为8微克/毫升。在7天或14天后，分别以约110或40毫克/千克体重的脂质体包裹丁胺卡那霉素或游离丁胺卡那霉素开始治疗。在前一个实验中，每周给药两到三次。在后一个实验中，每天给药5天。在最后一剂给药5天后处死动物。将肝脏、脾脏和肺匀浆，并在7H10琼脂上测定活菌数。方差分析及随后的Tukey HSD（真实显著差异）检验表明，与对照组相比，脂质体包裹的丁胺卡那霉素和游离丁胺卡那霉素均显著降低了各器官中的活菌数。与游离丁胺卡那霉素相比，脂质体包裹的丁胺卡那霉素显著降低了肝脏和脾脏中的活菌数。活性剂的脂质体包裹似乎是一种有前景的治疗鸟分枝杆菌复合群感染的方法。
